Baxter International Inc.
25.30USD
-0.3500 (-1.36%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BAX.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.52▼ | $0.53 | 2 | 7 |
| Next quarter | $0.61▼ | $0.66 | 1 | 8 |
| Current year | $2.04▲ | $1.92 | 12 | 0 |
| Next year | $2.04▲ | $2.01 | 1 | 0 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.37 | $0.56 | +0.19 (+52.5%) |
| 2026-03-31 | $0.31 | $0.36 | +0.05 (+15.9%) |
| 2025-12-31 | $0.54 | $0.44 | -0.10 (-17.8%) |
| 2025-09-30 | $0.6 | $0.69 | +0.09 (+15.4%) |
266 ratings from 30 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Barclays | Initiated | Underweight | $20 | Oct 7, 2026 |
| Citigroup | Maintained | Neutral | $28 $27 | Oct 5, 2026 |
| TD Cowen | Maintained | Hold | $24 $29 | Jul 31, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $19 $23 | Jul 31, 2026 |
| Stifel | Maintained | Hold | $24 $28 | Jul 31, 2026 |
| Citigroup | Upgraded from Sell | Neutral | $17 $28 | Jul 31, 2026 |
| UBS | Maintained | Neutral | $19 $25 | Jul 28, 2026 |
| Stifel | Maintained | Hold | $19 $24 | Jul 28, 2026 |
| TD Cowen | Maintained | Hold | $20 $24 | Jul 27, 2026 |
| Goldman Sachs | Maintained | Neutral | $19 $21 | Jul 15, 2026 |
| Evercore ISI Group | Maintained | Outperform | $22 $24 | Jul 6, 2026 |
| Citigroup | Downgraded from Neutral | Sell | $19 $17 | May 28, 2026 |
| Barclays | Maintained | Overweight | $25 $27 | May 4, 2026 |
| Evercore ISI Group | Maintained | Outperform | $23 $22 | Apr 6, 2026 |
| Citigroup | Maintained | Neutral | $21 $19 | Mar 11, 2026 |
| Goldman Sachs | Maintained | Neutral | $21 $17 | Feb 17, 2026 |
| Barclays | Maintained | Overweight | $30 $25 | Feb 13, 2026 |
| Barclays | Maintained | Overweight | $36 $30 | Jan 9, 2026 |
| Morgan Stanley | Maintained | Underweight | $19 $15 | Dec 2, 2025 |
| Citigroup | Maintained | Neutral | $26 $21 | Oct 31, 2025 |
| Goldman Sachs | Maintained | Neutral | $25 $22 | Oct 31, 2025 |
| UBS | Maintained | Neutral | $24 $21 | Oct 31, 2025 |
| Argus Research | Downgraded from Buy | Hold | — | Oct 31, 2025 |
| Evercore ISI Group | Maintained | Outperform | $33 $31 | Oct 7, 2025 |
| Barclays | Maintained | Overweight | $41 $36 | Aug 4, 2025 |
44 filings from 26 insiders · 0 buy / 0 sell over 6m
Officers and directors of BAX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hider Andrew P.Director; Officer, President and CEO | Tax | 54.3k | $25.70 | $1.39M | Sep 2, 2026 |
| Foster JulieOfficer, President, Front Line Care | Tax | 2.1k | $25.70 | $54k | Sep 2, 2026 |
| Teaff JamesOfficer, President, CCS | Tax | 750 | $25.48 | $19k | Sep 1, 2026 |
| ZIELINSKI ANITA A.Chief Financial Officer | Grant | 13.4k | — | — | Jun 1, 2026 |
| AMPOFO WILLIAM A. IIDirector | Grant | 12.8k | — | — | May 5, 2026 |
| WENDELL AMY MCBRIDEDirector | Grant | 12.8k | — | — | May 5, 2026 |
| SHAFER DAVID BRENTChairman of the Board | Grant | 12.8k | — | — | May 5, 2026 |
| MCDONNELL MICHAEL RDirector | Grant | 12.8k | — | — | May 5, 2026 |
| WILKES DAVID S. M.D.Director | Grant | 12.8k | — | — | May 5, 2026 |
| SCHLICHTING NANCY MDirector | Grant | 12.8k | — | — | May 5, 2026 |
| CRAIG JEFFREY ADirector | Grant | 12.8k | — | — | May 5, 2026 |
| MORRISON PATRICIA BDirector | Grant | 12.8k | — | — | May 5, 2026 |
| ZIELINSKI ANITA A.Officer | Grant | 30.9k | — | — | Feb 27, 2026 |
| ROSENBLOOM DAVID SGeneral Counsel | Grant | 26.7k | — | — | Feb 27, 2026 |
| HIDER ANDREW PChief Executive Officer | Grant | 201.8k | — | — | Feb 27, 2026 |
| CARLISLE CYNTHIAOfficer | Grant | 29.7k | — | — | Feb 27, 2026 |
| SORIANO MARIA CECILIAOfficer | Grant | 23.7k | — | — | Feb 27, 2026 |
| GRADE JOEL T.Chief Financial Officer | Grant | 42.7k | — | — | Feb 27, 2026 |
| MCDONNELL MICHAEL RDirector | Grant | 1.8k | — | — | Feb 13, 2026 |
| ROSENBLOOM DAVID SGeneral Counsel | Grant | 17.1k | — | — | Feb 9, 2026 |
No analyst notes on BAX yet.
Analyst Ratings
12 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 1 | 12 | 0 | 1 | Hold2.93 |
| 1 mo ago | 0 | 2 | 11 | 0 | 0 | Hold2.85 |
| 2 mo ago | 1 | 1 | 11 | 0 | 0 | Hold2.77 |
| 3 mo ago | 1 | 1 | 12 | 0 | 0 | Hold2.79 |
Members whose judged calls on BAX have played out most reliably.
No settled calls on BAX yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice